schliessen

Filtern

 

Bibliotheken

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data

Summary Background We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering... Full description

Journal Title: The Lancet (British edition) 2014-08-16, Vol.384 (9943), p.591-598
Main Author: Sundström, Johan
Other Authors: Arima, Hisatomi , Woodward, Mark , Jackson, Rod , Karmali, Kunal , Lloyd-Jones, Donald , Baigent, Colin , Emberson, Jonathan , Rahimi, Kazem , MacMahon, Stephen , Patel, Anushka , Perkovic, Vlado , Turnbull, Fiona , Neal, Bruce
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_DiVA_org_uu_231995
title: Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
format: Article
creator:
  • Sundström, Johan
  • Arima, Hisatomi
  • Woodward, Mark
  • Jackson, Rod
  • Karmali, Kunal
  • Lloyd-Jones, Donald
  • Baigent, Colin
  • Emberson, Jonathan
  • Rahimi, Kazem
  • MacMahon, Stephen
  • Patel, Anushka
  • Perkovic, Vlado
  • Turnbull, Fiona
  • Neal, Bruce
subjects:
  • Abridged Index Medicus
  • Anticholesteremic agents
  • Antihypertensive Agents
  • Antihypertensive Agents - therapeutic use
  • Antihypertensive drugs
  • Biological and medical sciences
  • Blood Pressure
  • Blood Pressure - drug effects
  • Cardiovascular Diseases
  • Cardiovascular Diseases - prevention & control
  • Clinical Medicine
  • Decision Making
  • Drug therapy
  • Endocrinology and Diabetes
  • Endokrinologi och diabetes
  • General aspects
  • Geriatrics
  • Geriatrik
  • Health aspects
  • Heart attack
  • Humans
  • Hypertension
  • Hypertension - drug therapy
  • Internal Medicine
  • Klinisk medicin
  • Medical and Health Sciences
  • Medical research
  • Medical sciences
  • Medicin och hälsovetenskap
  • Medicine, Experimental
  • Risk Assessment
  • Risk Factors
  • Usage
ispartof: The Lancet (British edition), 2014-08-16, Vol.384 (9943), p.591-598
description: Summary Background We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering therapy. Methods This meta-analysis included individual participant data from trials that randomly assigned patients to either blood pressure-lowering drugs or placebo, or to more intensive or less intensive blood pressure-lowering regimens. The primary outcome was total major cardiovascular events, consisting of stroke, heart attack, heart failure, or cardiovascular death. Participants were separated into four categories of baseline 5-year major cardiovascular risk using a risk prediction equation developed from the placebo groups of the included trials (21%). Findings 11 trials and 26 randomised groups met the inclusion criteria, and included 67 475 individuals, of whom 51 917 had available data for the calculation of the risk equations. 4167 (8%) had a cardiovascular event during a median of 4·0 years (IQR 3·4–4·4) of follow-up. The mean estimated baseline levels of 5-year cardiovascular risk for each of the four risk groups were 6·0% (SD 2·0), 12·1% (1·5), 17·7% (1·7), and 26·8% (5·4). In each consecutive higher risk group, blood pressure-lowering treatment reduced the risk of cardiovascular events relatively by 18% (95% CI 7–27), 15% (4–25), 13% (2–22), and 15% (5–24), respectively (p=0·30 for trend). However, in absolute terms, treating 1000 patients in each group with blood pressure-lowering treatment for 5 years would prevent 14 (95% CI 8–21), 20 (8–31), 24 (8–40), and 38 (16–61) cardiovascular events, respectively (p=0·04 for trend). Interpretation Lowering blood pressure provides similar relative protection at all levels of baseline cardiovascular risk, but progressively greater absolute risk reductions as baseline risk increases. These results support the use of predicted baseline cardiovascular disease risk equations to inform blood pressure-lowering treatment decisions. Funding None.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8075013
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_DiVA_org_uu_231995
sourceformatXML
sourcesystemPC
galeidA522444089
sourcerecordidA522444089
originalsourceidFETCH-LOGICAL-c860t-4bef0e1ed42c726e2fd689b9a4469eb070fb5d0c8469268e67fb23492a1c8b1b3
addsrcrecordideNqNk1tv1DAQhSMEglL4CaC8gEBqiu21cwEJVMpVqsQDFyHxYE3sydbFay-206r_Hu-mtEuFaJWHxNE3x6MzZ4riASW7lND62WdCOanqZlY_ofxpTRlllbhRbFHe8Erw5vvNYuscuVPcjfGIEMJrIm4Xd5igM9o17VZx9Np6r8tlwBjHgJX1JxiMm5cpIKQFulT2EFGX3pUKgjb-GKIaLYQymPjzeQnlAhNU4MCeRhNLP5TGaXNs9Ai2XEIyKw0NCe4VtwawEe-fvbeLr-_eftn_UB18ev9xf--gUm1NUsV7HAhS1JyphtXIBl23Xd8B53WHPWnI0AtNVJuPrG6xboaezXjHgKq2p_1su9iZdOMJLsdeLoNZQDiVHox8Y77tSR_mchwlyxZ0IuNPJnwZ_K8RY5ILExVaCw79GCUVgmdPm7rN6O6EzsGiNG7wKYDKj8aFUd7hYPL_PcEY55y03XULZk0nSJunlQse_qNAbio-3gAOEWw6jN6OyXgX_776v-DmlTsbYD9G43IWjItmfpjiHMZ4Sfca-Ka6mHAVfIwBh_NxUCJXQZbrIMtVSiXlch1kKS6MyBNcoD6v-pPcDDw6A3IewQ4BnDLxgmuzYree2YtLDSiTYOVCdtbYK9v4MVU7CJvyYZyv87TMO7M-OJu_e2sUTAZDD61C0UpFeSt5XkgJuiESB9HVnFHd95jVX03qmNfh2GCQUeV1UahNQJWk9ubK_l5eUlDWuNyF_YmnGI_8GPJi5hDLyCSZRFYalK8VxOw3LnhUZA
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1554474768
display
typearticle
titleBlood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
sourceAlma/SFX Local Collection
creatorSundström, Johan ; Arima, Hisatomi ; Woodward, Mark ; Jackson, Rod ; Karmali, Kunal ; Lloyd-Jones, Donald ; Baigent, Colin ; Emberson, Jonathan ; Rahimi, Kazem ; MacMahon, Stephen ; Patel, Anushka ; Perkovic, Vlado ; Turnbull, Fiona ; Neal, Bruce
creatorcontribSundström, Johan ; Arima, Hisatomi ; Woodward, Mark ; Jackson, Rod ; Karmali, Kunal ; Lloyd-Jones, Donald ; Baigent, Colin ; Emberson, Jonathan ; Rahimi, Kazem ; MacMahon, Stephen ; Patel, Anushka ; Perkovic, Vlado ; Turnbull, Fiona ; Neal, Bruce ; The Blood Pressure Lowering Treatment Trialists' Collaboration ; Blood Pressure Lowering Treatment Trialists' Collaboration
descriptionSummary Background We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering therapy. Methods This meta-analysis included individual participant data from trials that randomly assigned patients to either blood pressure-lowering drugs or placebo, or to more intensive or less intensive blood pressure-lowering regimens. The primary outcome was total major cardiovascular events, consisting of stroke, heart attack, heart failure, or cardiovascular death. Participants were separated into four categories of baseline 5-year major cardiovascular risk using a risk prediction equation developed from the placebo groups of the included trials (<11%, 11–15%, 15–21%, >21%). Findings 11 trials and 26 randomised groups met the inclusion criteria, and included 67 475 individuals, of whom 51 917 had available data for the calculation of the risk equations. 4167 (8%) had a cardiovascular event during a median of 4·0 years (IQR 3·4–4·4) of follow-up. The mean estimated baseline levels of 5-year cardiovascular risk for each of the four risk groups were 6·0% (SD 2·0), 12·1% (1·5), 17·7% (1·7), and 26·8% (5·4). In each consecutive higher risk group, blood pressure-lowering treatment reduced the risk of cardiovascular events relatively by 18% (95% CI 7–27), 15% (4–25), 13% (2–22), and 15% (5–24), respectively (p=0·30 for trend). However, in absolute terms, treating 1000 patients in each group with blood pressure-lowering treatment for 5 years would prevent 14 (95% CI 8–21), 20 (8–31), 24 (8–40), and 38 (16–61) cardiovascular events, respectively (p=0·04 for trend). Interpretation Lowering blood pressure provides similar relative protection at all levels of baseline cardiovascular risk, but progressively greater absolute risk reductions as baseline risk increases. These results support the use of predicted baseline cardiovascular disease risk equations to inform blood pressure-lowering treatment decisions. Funding None.
identifier
0ISSN: 0140-6736
1ISSN: 1474-547X
2EISSN: 1474-547X
3DOI: 10.1016/S0140-6736(14)61212-5
4PMID: 25131978
5CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAbridged Index Medicus ; Anticholesteremic agents ; Antihypertensive Agents ; Antihypertensive Agents - therapeutic use ; Antihypertensive drugs ; Biological and medical sciences ; Blood Pressure ; Blood Pressure - drug effects ; Cardiovascular Diseases ; Cardiovascular Diseases - prevention & control ; Clinical Medicine ; Decision Making ; Drug therapy ; Endocrinology and Diabetes ; Endokrinologi och diabetes ; General aspects ; Geriatrics ; Geriatrik ; Health aspects ; Heart attack ; Humans ; Hypertension ; Hypertension - drug therapy ; Internal Medicine ; Klinisk medicin ; Medical and Health Sciences ; Medical research ; Medical sciences ; Medicin och hälsovetenskap ; Medicine, Experimental ; Risk Assessment ; Risk Factors ; Usage
ispartofThe Lancet (British edition), 2014-08-16, Vol.384 (9943), p.591-598
rights
0Elsevier Ltd
12014 Elsevier Ltd
2info:eu-repo/semantics/closedAccess
32015 INIST-CNRS
4Copyright © 2014 Elsevier Ltd. All rights reserved.
5COPYRIGHT 2014 Elsevier B.V.
lds50peer_reviewed
citedbyFETCH-LOGICAL-c860t-4bef0e1ed42c726e2fd689b9a4469eb070fb5d0c8469268e67fb23492a1c8b1b3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28673968$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25131978$$D View this record in MEDLINE/PubMed
2$$Uhttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-231995$$DView record from Swedish Publication Index
search
creatorcontrib
0Sundström, Johan
1Arima, Hisatomi
2Woodward, Mark
3Jackson, Rod
4Karmali, Kunal
5Lloyd-Jones, Donald
6Baigent, Colin
7Emberson, Jonathan
8Rahimi, Kazem
9MacMahon, Stephen
10Patel, Anushka
11Perkovic, Vlado
12Turnbull, Fiona
13Neal, Bruce
14The Blood Pressure Lowering Treatment Trialists' Collaboration
15Blood Pressure Lowering Treatment Trialists' Collaboration
title
0Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering therapy. Methods This meta-analysis included individual participant data from trials that randomly assigned patients to either blood pressure-lowering drugs or placebo, or to more intensive or less intensive blood pressure-lowering regimens. The primary outcome was total major cardiovascular events, consisting of stroke, heart attack, heart failure, or cardiovascular death. Participants were separated into four categories of baseline 5-year major cardiovascular risk using a risk prediction equation developed from the placebo groups of the included trials (<11%, 11–15%, 15–21%, >21%). Findings 11 trials and 26 randomised groups met the inclusion criteria, and included 67 475 individuals, of whom 51 917 had available data for the calculation of the risk equations. 4167 (8%) had a cardiovascular event during a median of 4·0 years (IQR 3·4–4·4) of follow-up. The mean estimated baseline levels of 5-year cardiovascular risk for each of the four risk groups were 6·0% (SD 2·0), 12·1% (1·5), 17·7% (1·7), and 26·8% (5·4). In each consecutive higher risk group, blood pressure-lowering treatment reduced the risk of cardiovascular events relatively by 18% (95% CI 7–27), 15% (4–25), 13% (2–22), and 15% (5–24), respectively (p=0·30 for trend). However, in absolute terms, treating 1000 patients in each group with blood pressure-lowering treatment for 5 years would prevent 14 (95% CI 8–21), 20 (8–31), 24 (8–40), and 38 (16–61) cardiovascular events, respectively (p=0·04 for trend). Interpretation Lowering blood pressure provides similar relative protection at all levels of baseline cardiovascular risk, but progressively greater absolute risk reductions as baseline risk increases. These results support the use of predicted baseline cardiovascular disease risk equations to inform blood pressure-lowering treatment decisions. Funding None.
subject
0Abridged Index Medicus
1Anticholesteremic agents
2Antihypertensive Agents
3Antihypertensive Agents - therapeutic use
4Antihypertensive drugs
5Biological and medical sciences
6Blood Pressure
7Blood Pressure - drug effects
8Cardiovascular Diseases
9Cardiovascular Diseases - prevention & control
10Clinical Medicine
11Decision Making
12Drug therapy
13Endocrinology and Diabetes
14Endokrinologi och diabetes
15General aspects
16Geriatrics
17Geriatrik
18Health aspects
19Heart attack
20Humans
21Hypertension
22Hypertension - drug therapy
23Internal Medicine
24Klinisk medicin
25Medical and Health Sciences
26Medical research
27Medical sciences
28Medicin och hälsovetenskap
29Medicine, Experimental
30Risk Assessment
31Risk Factors
32Usage
issn
00140-6736
11474-547X
21474-547X
fulltexttrue
rsrctypearticle
creationdate2014
recordtypearticle
recordideNqNk1tv1DAQhSMEglL4CaC8gEBqiu21cwEJVMpVqsQDFyHxYE3sydbFay-206r_Hu-mtEuFaJWHxNE3x6MzZ4riASW7lND62WdCOanqZlY_ofxpTRlllbhRbFHe8Erw5vvNYuscuVPcjfGIEMJrIm4Xd5igM9o17VZx9Np6r8tlwBjHgJX1JxiMm5cpIKQFulT2EFGX3pUKgjb-GKIaLYQymPjzeQnlAhNU4MCeRhNLP5TGaXNs9Ai2XEIyKw0NCe4VtwawEe-fvbeLr-_eftn_UB18ev9xf--gUm1NUsV7HAhS1JyphtXIBl23Xd8B53WHPWnI0AtNVJuPrG6xboaezXjHgKq2p_1su9iZdOMJLsdeLoNZQDiVHox8Y77tSR_mchwlyxZ0IuNPJnwZ_K8RY5ILExVaCw79GCUVgmdPm7rN6O6EzsGiNG7wKYDKj8aFUd7hYPL_PcEY55y03XULZk0nSJunlQse_qNAbio-3gAOEWw6jN6OyXgX_776v-DmlTsbYD9G43IWjItmfpjiHMZ4Sfca-Ka6mHAVfIwBh_NxUCJXQZbrIMtVSiXlch1kKS6MyBNcoD6v-pPcDDw6A3IewQ4BnDLxgmuzYree2YtLDSiTYOVCdtbYK9v4MVU7CJvyYZyv87TMO7M-OJu_e2sUTAZDD61C0UpFeSt5XkgJuiESB9HVnFHd95jVX03qmNfh2GCQUeV1UahNQJWk9ubK_l5eUlDWuNyF_YmnGI_8GPJi5hDLyCSZRFYalK8VxOw3LnhUZA
startdate20140816
enddate20140816
creator
0Sundström, Johan
1Arima, Hisatomi
2Woodward, Mark
3Jackson, Rod
4Karmali, Kunal
5Lloyd-Jones, Donald
6Baigent, Colin
7Emberson, Jonathan
8Rahimi, Kazem
9MacMahon, Stephen
10Patel, Anushka
11Perkovic, Vlado
12Turnbull, Fiona
13Neal, Bruce
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
scope
05DI
15DJ
2QVL
3IQODW
4CGR
5CUY
6CVF
7ECM
8EIF
9NPM
10AAYXX
11CITATION
12BKMMT
13BSHEE
147X8
15ADTPV
sort
creationdate20140816
titleBlood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
authorSundström, Johan ; Arima, Hisatomi ; Woodward, Mark ; Jackson, Rod ; Karmali, Kunal ; Lloyd-Jones, Donald ; Baigent, Colin ; Emberson, Jonathan ; Rahimi, Kazem ; MacMahon, Stephen ; Patel, Anushka ; Perkovic, Vlado ; Turnbull, Fiona ; Neal, Bruce
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c860t-4bef0e1ed42c726e2fd689b9a4469eb070fb5d0c8469268e67fb23492a1c8b1b3
rsrctypearticles
prefilterarticles
languageeng
creationdate2014
topic
0Abridged Index Medicus
1Anticholesteremic agents
2Antihypertensive Agents
3Antihypertensive Agents - therapeutic use
4Antihypertensive drugs
5Biological and medical sciences
6Blood Pressure
7Blood Pressure - drug effects
8Cardiovascular Diseases
9Cardiovascular Diseases - prevention & control
10Clinical Medicine
11Decision Making
12Drug therapy
13Endocrinology and Diabetes
14Endokrinologi och diabetes
15General aspects
16Geriatrics
17Geriatrik
18Health aspects
19Heart attack
20Humans
21Hypertension
22Hypertension - drug therapy
23Internal Medicine
24Klinisk medicin
25Medical and Health Sciences
26Medical research
27Medical sciences
28Medicin och hälsovetenskap
29Medicine, Experimental
30Risk Assessment
31Risk Factors
32Usage
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Sundström, Johan
1Arima, Hisatomi
2Woodward, Mark
3Jackson, Rod
4Karmali, Kunal
5Lloyd-Jones, Donald
6Baigent, Colin
7Emberson, Jonathan
8Rahimi, Kazem
9MacMahon, Stephen
10Patel, Anushka
11Perkovic, Vlado
12Turnbull, Fiona
13Neal, Bruce
14The Blood Pressure Lowering Treatment Trialists' Collaboration
15Blood Pressure Lowering Treatment Trialists' Collaboration
collection
0NARCIS
1NARCIS: Datasets
2NARCIS:Publications
3Pascal-Francis
4Medline
5MEDLINE
6MEDLINE (Ovid)
7MEDLINE
8MEDLINE
9PubMed
10CrossRef
11Gale General OneFile (A&I only)
12Academic OneFile (A&I only)
13MEDLINE - Academic
14SwePub
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Sundström, Johan
1Arima, Hisatomi
2Woodward, Mark
3Jackson, Rod
4Karmali, Kunal
5Lloyd-Jones, Donald
6Baigent, Colin
7Emberson, Jonathan
8Rahimi, Kazem
9MacMahon, Stephen
10Patel, Anushka
11Perkovic, Vlado
12Turnbull, Fiona
13Neal, Bruce
aucorp
0The Blood Pressure Lowering Treatment Trialists' Collaboration
1Blood Pressure Lowering Treatment Trialists' Collaboration
formatjournal
genrearticle
ristypeJOUR
atitleBlood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
jtitleThe Lancet (British edition)
addtitleLancet
date2014-08-16
risdate2014
volume384
issue9943
spage591
epage598
pages591-598
issn
00140-6736
11474-547X
eissn1474-547X
codenLANCAO
abstractSummary Background We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering therapy. Methods This meta-analysis included individual participant data from trials that randomly assigned patients to either blood pressure-lowering drugs or placebo, or to more intensive or less intensive blood pressure-lowering regimens. The primary outcome was total major cardiovascular events, consisting of stroke, heart attack, heart failure, or cardiovascular death. Participants were separated into four categories of baseline 5-year major cardiovascular risk using a risk prediction equation developed from the placebo groups of the included trials (<11%, 11–15%, 15–21%, >21%). Findings 11 trials and 26 randomised groups met the inclusion criteria, and included 67 475 individuals, of whom 51 917 had available data for the calculation of the risk equations. 4167 (8%) had a cardiovascular event during a median of 4·0 years (IQR 3·4–4·4) of follow-up. The mean estimated baseline levels of 5-year cardiovascular risk for each of the four risk groups were 6·0% (SD 2·0), 12·1% (1·5), 17·7% (1·7), and 26·8% (5·4). In each consecutive higher risk group, blood pressure-lowering treatment reduced the risk of cardiovascular events relatively by 18% (95% CI 7–27), 15% (4–25), 13% (2–22), and 15% (5–24), respectively (p=0·30 for trend). However, in absolute terms, treating 1000 patients in each group with blood pressure-lowering treatment for 5 years would prevent 14 (95% CI 8–21), 20 (8–31), 24 (8–40), and 38 (16–61) cardiovascular events, respectively (p=0·04 for trend). Interpretation Lowering blood pressure provides similar relative protection at all levels of baseline cardiovascular risk, but progressively greater absolute risk reductions as baseline risk increases. These results support the use of predicted baseline cardiovascular disease risk equations to inform blood pressure-lowering treatment decisions. Funding None.
copKidlington
pubElsevier Ltd
pmid25131978
doi10.1016/S0140-6736(14)61212-5